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Background: Venous-arterial extracorporeal membrane oxygenation (ECMO) has been used successfully for treatment of cardiogenic shock 
or cardiac arrest. The exact complication rate is not well understood, in part due to small study sizes. In the absence of large clinical trials, 
performance of pooled analysis represents the best method for ascertaining complication rates for ECMO.
methods: A systematic MEDLINE search was conducted on ECMO for treatment of cardiac shock or cardiac arrest, updated up to July 2012. 
Studies with N>30 published in the year 2000 or later, which reported complication rates for ECMO were included. Specific complications analyzed 
included lower extremity ischemia, fasciotomy, amputation, bleed, stroke, neurologic sequelae, acute kidney injury, systemic infection, and re-
thoracotomy for bleeding or tamponade. For studies that included overlapping patients, the largest study was included and the others excluded. 
Cochran’s Q and I2 were calculated. A conservative random effects model was chosen for all analyses.
results: 26 studies were included in the analyses encompassing 277-1,320 patients depending on the specific complication analyzed. Results are 
summarized in Table 1.
conclusions: While ECMO could improve survival of patients with advanced heart disease, there is significant associated morbidity with 
performance of this intervention. These findings could be incorporated in the risk benefit analysis when initiation of ECMO for cardiogenic shock is 
being considered. 
Table 1. Complications of ECMO
Lower 
Extremity 
Ischemia
Fasciotomy Lower Extremity Amputation Bleed Stroke Neurologic
Acute Kidney 
Insufficiency
Requiring Renal 
Replacement 
Therapy
Systemic 
Infection
Re-thoracotomy 
for bleed or 
tamponade
Reported Rate Min, Max, % 3, 33 4, 21 1, 13 9, 64 1, 13 6, 50 30, 87 14, 87 15, 90 8, 87
Cumulative Rate 106/804 37/454 11/277 167/583 63/962 181/1022 158/343 707/1370 279/740 398/820
Number of Studies 13 7 5 8 6 9 6 13 9 6
Cochran’s Q 38.1 7.88 4.90 62.6 20.8 50.0 24.3 92.4 79.8 132
P Value Heterogeneity <0.01 Not Significant Not Significant <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01
I2, % 68.5 23.9 18.3 88.8 76.0 83.3 79.4 87.0 90.0 96.2
Pooled Estimate Rate, % 11.7 7.03 3.12 28.8 6.26 15.2 46.0 42.9 34.9 39.8
95% Confidence Interval, % 7.63-15.8 4.00-10.1 0.39-5.86 17.4-40.3 2.97-9.56 9.12-21.4 30.7-61.3 32.5-53.4 22.0-47.8 17.8-61.8
